When someone faces paraganglioma, understanding treatment options becomes essential for both managing symptoms and improving quality of life. These rare tumors, though often treatable, require careful medical attention and personalized care plans that depend on where the tumor is located, whether it produces hormones, and if it has spread to other areas.

Finding the Right Path in Paraganglioma Care

Treating paraganglioma involves more than just removing a tumor. The main goals of treatment focus on controlling the symptoms caused by excessive hormone release, preventing the tumor from growing larger or spreading, and helping patients return to their daily activities with minimal disruption. Because paragangliomas can appear in different parts of the body and behave differently from person to person, doctors create treatment plans based on the tumor’s location, size, whether it secretes hormones, and the patient’s overall health.^[1]

Medical teams typically include specialists from multiple fields working together. This might include surgeons who remove tumors, doctors who specialize in hormones (called endocrinologists), imaging specialists who help locate tumors precisely, and radiation experts. This team approach ensures that every aspect of the patient’s condition receives proper attention.^[3]

Importantly, not all paragangliomas require immediate aggressive treatment. Some tumors grow very slowly and don’t cause symptoms. In these cases, doctors might recommend careful monitoring without intervention, checking the tumor regularly through imaging scans and physical examinations. This approach, often called active surveillance or “watch and wait,” helps avoid unnecessary risks from treatment when the tumor poses little immediate threat.^[3][7]

The landscape of paraganglioma treatment continues to evolve. Medical societies have established standard treatments that have proven effective over time, but researchers are also actively investigating new therapies through clinical trials. These studies test promising approaches that might become tomorrow’s standard treatments, offering hope for better outcomes and fewer side effects.

Standard Medical Approaches for Paraganglioma

The cornerstone of paraganglioma treatment remains surgical removal of the tumor when possible. Surgery aims to completely remove the growth, which often resolves symptoms and prevents future complications. The extent and complexity of surgery depend heavily on where the tumor is located. For example, a small paraganglioma near the middle ear might require only a brief outpatient procedure, while a tumor on the jugular vein demands more extensive inpatient surgery with intensive care afterward.^[7]

Before surgery, patients with hormone-secreting paragangliomas need special preparation. These tumors can release large amounts of catecholamines—hormones like adrenaline and noradrenaline that increase heart rate and blood pressure. To prevent dangerous spikes in blood pressure during surgery, doctors prescribe medications to block these hormones’ effects. The most common approach uses drugs called alpha blockers, which are medications that help control high blood pressure by blocking the action of adrenaline on blood vessels. These might be followed by beta blockers, another type of blood pressure medication. This preparation typically lasts several days to weeks before the operation.^[3][8]

Sometimes surgeons combine surgery with a procedure called embolization. This technique involves blocking the blood vessels that feed the tumor, reducing its blood supply before removal. By cutting off the tumor’s nutrition source, embolization can shrink it and make surgical removal safer and easier. This is particularly helpful for paragangliomas in the head and neck area, where tumors are often highly vascular—meaning they have many blood vessels running through them.^[7]

For patients who cannot undergo surgery due to the tumor’s location, their overall health, or other factors, radiation therapy offers an alternative. One particularly effective form is stereotactic radiosurgery, despite its name not actually involving surgery. This technique delivers very precise pulses of high-dose radiation directly to the tumor while limiting exposure to surrounding healthy tissues. A system called CyberKnife, developed for this purpose, uses robotic technology to target the tumor from multiple angles. While radiation cannot remove the tumor, it can be very effective at stopping its growth and controlling symptoms.^[7]

Radiation therapy typically involves multiple treatment sessions over several weeks. Patients might receive treatment five days a week for six weeks, for example. The process itself is painless, though side effects can occur depending on where the tumor is located. These might include fatigue, skin irritation in the treatment area, or temporary worsening of symptoms as the tumor swells slightly before shrinking.^[7]

Many patients receive what doctors call combination treatment—using more than one approach together or in sequence. For instance, someone might have surgery to remove the bulk of a tumor, followed by radiation to treat any remaining cells. Or they might start with radiation to shrink a tumor before surgery. The treatment plan might also include active surveillance after initial treatment, with regular check-ups to catch any signs of the tumor returning early.^[7]

Emerging Treatments Being Tested in Clinical Research

Clinical trials represent the frontier of paraganglioma treatment, where researchers test new approaches that might become standard care in the future. These studies carefully evaluate whether experimental treatments are safe and whether they work better than existing options. Patients who participate in clinical trials gain access to cutting-edge therapies while contributing to medical knowledge that helps future patients.

Clinical trials progress through distinct phases, each with specific goals. Phase I trials primarily focus on safety, testing whether a new treatment causes unacceptable side effects and determining the best dose to use. These typically involve small numbers of patients. Phase II trials expand to more participants and focus on whether the treatment actually works—does it shrink tumors, control symptoms, or slow disease progression? Finally, Phase III trials compare the new treatment directly against the current standard treatment to see which works better. These are large studies involving many medical centers and hundreds or even thousands of patients.^[7]

For paragangliomas that have spread to other parts of the body (called metastatic paraganglioma), researchers are investigating several promising approaches. While standard local treatments like surgery and radiation work well for tumors confined to one area, metastatic disease requires treatments that can reach cancer cells throughout the body.

One area of active research involves drugs that target the specific molecular pathways that paraganglioma cells use to grow and spread. Scientists have identified mutations in approximately 20 different genes that may lead to paraganglioma development. These genes include SDHB, SDHD, SDHC, SDHA (which all affect an enzyme called succinate dehydrogenase), as well as VHL, RET, and NF1, among others.^[3][8] Understanding these genetic changes helps researchers design drugs that specifically block the faulty signals these mutated genes produce.

Some clinical trials are testing medications that interfere with how paraganglioma cells use energy or grow new blood vessels to support their expansion. Tumors need to develop their own blood supply to grow beyond a tiny size, a process called angiogenesis. Drugs that block angiogenesis essentially starve tumors by preventing them from building the infrastructure they need. This approach has shown promise in various cancers and is now being evaluated specifically for paragangliomas.

Another innovative approach being studied involves radioactive treatments that specifically target paraganglioma cells. These therapies use radioactive substances that paraganglioma cells preferentially absorb. Once inside the tumor cells, the radioactive material delivers targeted radiation that kills the cell from within while sparing surrounding normal tissue. One such approach uses a radioactive tracer similar to those used in certain imaging tests but at much higher doses designed to treat rather than just detect tumors.

Researchers are also exploring whether existing cancer drugs approved for other tumor types might help paraganglioma patients. This approach, called drug repurposing, can potentially bring treatments to patients faster since the drugs have already passed safety testing for other uses. Some chemotherapy drugs and targeted therapies approved for other neuroendocrine tumors are being evaluated in paraganglioma clinical trials.

The location of clinical trials varies widely. Major medical centers in the United States, Europe, Australia, and other regions conduct paraganglioma research. Some trials specifically recruit patients from multiple countries to gather data more quickly. Patient eligibility for trials depends on many factors including the tumor’s characteristics, whether previous treatments were tried, the patient’s overall health, and sometimes specific genetic features of their tumor.^[7]

Early results from some ongoing trials have shown encouraging signs. Certain targeted therapies have demonstrated the ability to slow tumor growth in patients whose paragangliomas had stopped responding to standard treatments. Some patients have experienced reductions in tumor size or stabilization of disease that had previously been progressing. Additionally, some experimental treatments have shown favorable safety profiles with manageable side effects.

Genetic testing has become increasingly important in paraganglioma treatment planning and may influence eligibility for certain clinical trials. Between 30% and 40% of paragangliomas are hereditary, meaning they result from inherited genetic mutations.^[4][13] Knowing whether someone has a genetic form of paraganglioma can help predict tumor behavior, guide treatment choices, and inform family members who might be at risk. Some clinical trials specifically seek patients with particular genetic mutations, as certain treatments may work better for tumors driven by specific genetic changes.

Most common treatment methods

• Surgery
  • Complete surgical removal of the tumor is the primary treatment when possible
  • Surgery extent depends on tumor location—from brief outpatient procedures for small tumors to extensive operations requiring intensive care
  • Pre-surgical preparation with alpha blockers and sometimes beta blockers is essential for hormone-secreting tumors to prevent dangerous blood pressure spikes during surgery
  • Embolization may be performed before surgery to reduce tumor blood supply and make removal safer
• Radiation therapy
  • Stereotactic radiosurgery or CyberKnife delivers precise high-dose radiation to tumors
  • Used when surgery is not possible or as additional treatment after surgery
  • Cannot remove tumors but effectively stops growth and controls symptoms
  • Typically involves multiple treatment sessions over several weeks
• Medical management with blood pressure medications
  • Alpha blockers control blood pressure by blocking adrenaline effects on blood vessels
  • Beta blockers may be added to control heart rate
  • Used both before surgery and for long-term symptom control in patients who cannot have surgery
• Active surveillance
  • Regular monitoring with imaging scans and physical exams without immediate intervention
  • Appropriate for slow-growing tumors that don’t cause symptoms
  • Avoids treatment risks when the tumor poses little immediate threat
• Experimental treatments in clinical trials
  • Targeted therapies that block specific molecular pathways paraganglioma cells use to grow
  • Anti-angiogenesis drugs that prevent tumors from developing blood supply
  • Radioactive treatments that specifically target and kill paraganglioma cells
  • Repurposed drugs originally approved for other tumor types